Youn H. Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Youn H. Kim has a total of 437 co-authors. Here are the top co-authors by number of shared publications:
- Michael S. Khodadoust
Stanford Cancer Institute, United States
10 shared publications - Henry Miles Prince
Sir Peter MacCallum Department of Oncology University of Melbourne Parkville Victoria Australia
8 shared publications Madeleine Duvic
Department of Dermatology, The University of Texas—MD Anderson Cancer Center, Houston, TX
8 shared publicationsSean Whittaker
St Johns Institute of Dermatology, King’s College London, London, United Kingdom
8 shared publicationsRichard T. Hoppe
Youn H. Kim, Mahkam Tavallaee, Uma Sundram, Shufeng Li, Sima Rozati, Seema Nagpal, Michael Krathen, Sunil Reddy, Richard T. Hoppe, Annie Nguyen-Lin, Wen-Kai Weng, Randall Armstrong, and Ranjana H. Advani, Stanford University, Stanford, CA; Katrin A. Salva and Gary S. Wood, University of Wisconsin and William S. Middleton Memorial Veterans Hospital, Madison, WI; and Melissa Pulitzer and Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY
7 shared publications- Julia Jane Scarisbrick
Department of Dermatology University Hospital Birmingham Birmingham UK
6 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Rosai-Dorfman disease: a 30-year institutional study of clinical features, treatment patterns, and outcomes
- 4 September 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Open AccessRosai-Dorfman disease: a 30-year institutional study of clinical features, treatment patterns, and outcomes
- 25 August 2026
- Published by American Society of Hematology in Blood
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas
Despite advances in the molecular characterization of mature T and NK cell lymphomas, outcomes for these patients is poor especially those with relapsed/refractory (R/R) disease. These tumors possess mutations that often result in tonic T cell receptor (TCR) signaling and an immunosuppressive tumor microenvironment. Interleukin-2-inducible T cell kinase (ITK) plays an important role in TCR signaling and T cell differentiation. Soquelitinib is a covalent oral selective ITK inhibitor that blocks Th2 differentiation while sparing Th1 cells (Th1 skewing). We conducted a phase 1 trial with soquelitinib for the treatment of R/R peripheral T cell lymphomas to determine safety, target occupancy and antitumor activity. A dose escalation design was followed by an expansion cohort to confirm dosing and identify predictive characteristics. Seventy-five patients were enrolled. No dose-limiting toxicities were observed with doses up to 600mg BID and target occupancy exceeding 80% was established for 200mg BID dose. At the 200mg BID dose, number of prior lines of therapy was found to affect antitumor activity as durable complete and partial responses were seen in 37% patients with 1-3 prior therapies; no responses were seen in patients with >3. Objective and durable tumor responses were observed in various histologic subtypes. Blood and tumor biopsies indicated that soquelitinib treatment leads to Th1 skewing, reduction of T cell exhaustion and blockade of Th2 cells. These studies demonstrate soquelitinib is active in T cell lymphomas with a mechanism related to effects on malignant T cells and/or normal T effector cells. Trial registration: NCT03952078 at www.ClinicalTrials.gov.
- 25 August 2026
- Published by American Society of Hematology in Blood
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas
Despite advances in the molecular characterization of mature T and NK cell lymphomas, outcomes for these patients is poor especially those with relapsed/refractory (R/R) disease. These tumors possess mutations that often result in tonic T cell receptor (TCR) signaling and an immunosuppressive tumor microenvironment. Interleukin-2-inducible T cell kinase (ITK) plays an important role in TCR signaling and T cell differentiation. Soquelitinib is a covalent oral selective ITK inhibitor that blocks Th2 differentiation while sparing Th1 cells (Th1 skewing). We conducted a phase 1 trial with soquelitinib for the treatment of R/R peripheral T cell lymphomas to determine safety, target occupancy and antitumor activity. A dose escalation design was followed by an expansion cohort to confirm dosing and identify predictive characteristics. Seventy-five patients were enrolled. No dose-limiting toxicities were observed with doses up to 600mg BID and target occupancy exceeding 80% was established for 200mg BID dose. At the 200mg BID dose, number of prior lines of therapy was found to affect antitumor activity as durable complete and partial responses were seen in 37% patients with 1-3 prior therapies; no responses were seen in patients with >3. Objective and durable tumor responses were observed in various histologic subtypes. Blood and tumor biopsies indicated that soquelitinib treatment leads to Th1 skewing, reduction of T cell exhaustion and blockade of Th2 cells. These studies demonstrate soquelitinib is active in T cell lymphomas with a mechanism related to effects on malignant T cells and/or normal T effector cells. Trial registration: NCT03952078 at www.ClinicalTrials.gov.
- Open Access
- 4 August 2026
- Published by Wiley in Journal of Cutaneous Pathology
Primary Cutaneous Gamma‐Delta T‐Cell Lymphoma Complicating Long‐Standing Immunosuppressed Dermatomyositis
Primary cutaneous gamma‐delta T‐cell lymphoma (PCGD‐TCL) is a rare cytotoxic lymphoma with key oncogenic drivers in the JAK/STAT pathway. Also primarily involving the subcutaneous adipose tissue, subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) is more frequently encountered in scenarios of autoimmune disorders. SPTCL shares clinicopathologic overlap with lupus panniculitis. However, the link between autoimmunity and PCGD‐TCL is much less established, particularly in the setting of long‐standing, immunosuppressed dermatomyositis (DM). We report two cases of PCGD‐TCL arising in women with chronic anti‐TIF1‐γ DM following years of immunosuppressive therapy. Case 1 is a 47‐year‐old woman with a 19‐year history of DM on azathioprine/prednisone who developed rapidly progressive, painful subcutaneous nodules. Incisional biopsy confirmed a TCR‐delta+, CD8+ cytotoxic T‐cell lymphoproliferative disorder (TCLPD) compatible with PCGD‐TCL. She achieved complete remission following pralatrexate and subsequent allogeneic hematopoietic stem cell transplant. Case 2 is a 27‐year‐old woman with DM on mycophenolate/rituximab who developed subcutaneous nodules with an indolent course and some spontaneous regression. A biopsy revealed a similar panniculitic infiltrate with an atypical TCR‐delta+, CD8+ phenotype. Notably, both cases were negative for high‐risk JAK/STAT pathway mutations. These cases identify PCGD‐TCLPD/TCL as a potential complication of chronic, immunosuppressed DM. The shared, atypical CD8+ immunophenotype and absence of canonical driver mutations suggest a distinct pathogenic mechanism possibly linked to long‐term immune modulation. Unlike classic PCGD‐TCL, which is characterized by an aggressive course and < 2‐year median survival, the clinical courses in these two cases were variable, with one requiring transplant and the other showing indolent behavior and responsiveness to therapy.
- 4 August 2026
- Published by Wiley in Journal of Cutaneous Pathology
Open AccessPrimary Cutaneous Gamma‐Delta T‐Cell Lymphoma Complicating Long‐Standing Immunosuppressed Dermatomyositis
Primary cutaneous gamma‐delta T‐cell lymphoma (PCGD‐TCL) is a rare cytotoxic lymphoma with key oncogenic drivers in the JAK/STAT pathway. Also primarily involving the subcutaneous adipose tissue, subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) is more frequently encountered in scenarios of autoimmune disorders. SPTCL shares clinicopathologic overlap with lupus panniculitis. However, the link between autoimmunity and PCGD‐TCL is much less established, particularly in the setting of long‐standing, immunosuppressed dermatomyositis (DM). We report two cases of PCGD‐TCL arising in women with chronic anti‐TIF1‐γ DM following years of immunosuppressive therapy. Case 1 is a 47‐year‐old woman with a 19‐year history of DM on azathioprine/prednisone who developed rapidly progressive, painful subcutaneous nodules. Incisional biopsy confirmed a TCR‐delta+, CD8+ cytotoxic T‐cell lymphoproliferative disorder (TCLPD) compatible with PCGD‐TCL. She achieved complete remission following pralatrexate and subsequent allogeneic hematopoietic stem cell transplant. Case 2 is a 27‐year‐old woman with DM on mycophenolate/rituximab who developed subcutaneous nodules with an indolent course and some spontaneous regression. A biopsy revealed a similar panniculitic infiltrate with an atypical TCR‐delta+, CD8+ phenotype. Notably, both cases were negative for high‐risk JAK/STAT pathway mutations. These cases identify PCGD‐TCLPD/TCL as a potential complication of chronic, immunosuppressed DM. The shared, atypical CD8+ immunophenotype and absence of canonical driver mutations suggest a distinct pathogenic mechanism possibly linked to long‐term immune modulation. Unlike classic PCGD‐TCL, which is characterized by an aggressive course and < 2‐year median survival, the clinical courses in these two cases were variable, with one requiring transplant and the other showing indolent behavior and responsiveness to therapy.
- Open Access
Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy
Background: Mycosis fungoides (MF) and Sézary syndrome (SS) are the predominant cutaneous T-cell lymphomas. Although malignant T cells in MF/SS overexpress CCR4 and respond to the anti-CCR4 antibody mogamulizumab, skin response rates vary. We hypothesized that immune components within the tumor microenvironment contribute to differential outcomes. Methods: Imaging mass cytometry with a 37-antibody panel was used to characterize immune and structural elements in FFPE tissues from sixteen MF/SS patients (6 MF, 10 SS) treated with Mogamulizumab, including seven skin responders and nine non-responders. Single-cell phenotyping and spatial analyses were performed using the Visiopharm® Phenoplex™ platform, with supervision. Results: We identified 68,974 cells pre-treatment and 58,852 cells post-treatment. Malignant CD4+ T cells showed reduced baseline CD27, CD103, CD25, and ICOS expression compared with non-malignant CD4+ cells. Baseline MF lesions were enriched for IL-13+ and CD103+ malignant T cells, whereas SS lesions contained higher proportions of CD27+ and LAG3+ cells. IL 13+ malignant cells decreased after treatment, most prominently in MF. Myeloid profiles differed by disease and response: MF lesions exhibited baseline enrichment of M1-like macrophages (CD86+, HLA-DR+), while SS lesions were predominantly M2-polarized macrophages (CD163+, CD206+). Responders showed increased M1-like macrophages, whereas non-responders displayed reduced M1-features. An increase in DC3-like cells was observed in non-responders following treatment. Conclusions: This single-cell spatial atlas reveals shared and subtype-specific immune features in MF/SS. Th2-skewed malignant T-cell status and myeloid polarization correlate with clinical response, supporting their potential as spatial biomarkers for patient stratification in mogamulizumab therapy.
Open AccessDissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy
Background: Mycosis fungoides (MF) and Sézary syndrome (SS) are the predominant cutaneous T-cell lymphomas. Although malignant T cells in MF/SS overexpress CCR4 and respond to the anti-CCR4 antibody mogamulizumab, skin response rates vary. We hypothesized that immune components within the tumor microenvironment contribute to differential outcomes. Methods: Imaging mass cytometry with a 37-antibody panel was used to characterize immune and structural elements in FFPE tissues from sixteen MF/SS patients (6 MF, 10 SS) treated with Mogamulizumab, including seven skin responders and nine non-responders. Single-cell phenotyping and spatial analyses were performed using the Visiopharm® Phenoplex™ platform, with supervision. Results: We identified 68,974 cells pre-treatment and 58,852 cells post-treatment. Malignant CD4+ T cells showed reduced baseline CD27, CD103, CD25, and ICOS expression compared with non-malignant CD4+ cells. Baseline MF lesions were enriched for IL-13+ and CD103+ malignant T cells, whereas SS lesions contained higher proportions of CD27+ and LAG3+ cells. IL 13+ malignant cells decreased after treatment, most prominently in MF. Myeloid profiles differed by disease and response: MF lesions exhibited baseline enrichment of M1-like macrophages (CD86+, HLA-DR+), while SS lesions were predominantly M2-polarized macrophages (CD163+, CD206+). Responders showed increased M1-like macrophages, whereas non-responders displayed reduced M1-features. An increase in DC3-like cells was observed in non-responders following treatment. Conclusions: This single-cell spatial atlas reveals shared and subtype-specific immune features in MF/SS. Th2-skewed malignant T-cell status and myeloid polarization correlate with clinical response, supporting their potential as spatial biomarkers for patient stratification in mogamulizumab therapy.
- Top Cited Papers
- 2 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (14) , 1687-1692
A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification
Advanced mycosis fungoides (MF) and Sézary syndrome (SS) have a poor overall survival (OS) of 60 years (P < .001), raised serum lactate dehydrogenase (P = .005), and large-cell transformation in skin (P = .006). Modeling these 4 independent risk factors into a CLIPI found that there was a worse OS in high- vs low-risk (P < .001), high- vs intermediate-risk (P = .002) and intermediate- vs low-risk (P = .010) groups. Five-year OS was 63.3%, 44.7%, and 18.3% in the low-, intermediate-, and high-risk groups, respectively. In this advanced stage cohort there was a low 5-year survival and increasing stage was not associated with worsening survival. The use of CLIPI to stratify patients into risk groups has the potential to improve outcomes and aid optimal treatment selection. This trial was registered at www.ClinicalTrials.gov as #NCT02848274.
- 2 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (14) , 1687-1692
Top Cited PapersA new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification
Advanced mycosis fungoides (MF) and Sézary syndrome (SS) have a poor overall survival (OS) of 60 years (P < .001), raised serum lactate dehydrogenase (P = .005), and large-cell transformation in skin (P = .006). Modeling these 4 independent risk factors into a CLIPI found that there was a worse OS in high- vs low-risk (P < .001), high- vs intermediate-risk (P = .002) and intermediate- vs low-risk (P = .010) groups. Five-year OS was 63.3%, 44.7%, and 18.3% in the low-, intermediate-, and high-risk groups, respectively. In this advanced stage cohort there was a low 5-year survival and increasing stage was not associated with worsening survival. The use of CLIPI to stratify patients into risk groups has the potential to improve outcomes and aid optimal treatment selection. This trial was registered at www.ClinicalTrials.gov as #NCT02848274.
- Top Cited PapersOpen Access
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (10) , 1198-1209
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
PURPOSE: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles. Patients in the primary efficacy analysis set (PEAS) were required to have stage IA-IIIB CTCL (mycosis fungoides and/or Sézary syndrome) and at least ≥one previous systemic therapy. The primary efficacy end point was objective response rate (ORR) using the Global Response Score. Secondary end points were duration of response (DOR), time to response (TTR), skin tumor burden, and safety and tolerability. RESULTS: The PEAS included 69 patients (median age, 64.0 years). The ORR was 36.2% (95% CI, 25.0 to 48.7), including 8.7% with complete response. The median DOR was 8.9 months (95% CI, 5.0 to not estimable), and the median (Q1-Q3) TTR was 1.4 (0.7-2.1) months. A total of 84.4% of patients showed decreased skin tumor burden, with 48.4% showing a ≥50% decrease. Treatment-emergent adverse events (TEAEs) of special interest, most of which were grade 1 or 2, included infusion reaction (73.9%), hypersensitivity (68.1%), hepatotoxicity (36.2%), and capillary leak syndrome (20.3% [grade ≥3, 5.8%]). Other common TEAEs were nausea (43.5%) and fatigue (31.9%). CONCLUSION: Efficacy and safety results show that DD-cxdl would potentially fulfill a serious, unmet medical need for patients with R/R CTCL.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (10) , 1198-1209
Top Cited PapersOpen AccessEfficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
PURPOSE: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles. Patients in the primary efficacy analysis set (PEAS) were required to have stage IA-IIIB CTCL (mycosis fungoides and/or Sézary syndrome) and at least ≥one previous systemic therapy. The primary efficacy end point was objective response rate (ORR) using the Global Response Score. Secondary end points were duration of response (DOR), time to response (TTR), skin tumor burden, and safety and tolerability. RESULTS: The PEAS included 69 patients (median age, 64.0 years). The ORR was 36.2% (95% CI, 25.0 to 48.7), including 8.7% with complete response. The median DOR was 8.9 months (95% CI, 5.0 to not estimable), and the median (Q1-Q3) TTR was 1.4 (0.7-2.1) months. A total of 84.4% of patients showed decreased skin tumor burden, with 48.4% showing a ≥50% decrease. Treatment-emergent adverse events (TEAEs) of special interest, most of which were grade 1 or 2, included infusion reaction (73.9%), hypersensitivity (68.1%), hepatotoxicity (36.2%), and capillary leak syndrome (20.3% [grade ≥3, 5.8%]). Other common TEAEs were nausea (43.5%) and fatigue (31.9%). CONCLUSION: Efficacy and safety results show that DD-cxdl would potentially fulfill a serious, unmet medical need for patients with R/R CTCL.
- Open Access
- 27 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (8)
Addiction of primary cutaneous γδ T cell lymphomas to JAK/STAT signaling
- 27 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (8)
Open AccessAddiction of primary cutaneous γδ T cell lymphomas to JAK/STAT signaling
- Open Access
- 8 February 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (6) , 1100-1110
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma
In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], n = 29); PTCL-not otherwise specified [NOS], n = 11; and Other, n = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 complete responses [CR],9 partial responses [PR], and 14 stable disease); median time to response was 1.9 months. ORR was 51.9% for AITL/TFH (10 CR, 4 PR) and 31.8% for Other (2 CR, 5 PR); median duration of response was 12.9 and 5.3 months, respectively. The most common grade ≥3 treatment-emergent adverse events were asymptomatic amylase elevation (23.1%), anemia (20.0%), and asymptomatic lipase elevation (18.5%). These data suggest clinical activity and acceptable tolerability for cerdulatinib in patients with relapsed/refractory PTCL.
- 8 February 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (6) , 1100-1110
Open AccessResults from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma
In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], n = 29); PTCL-not otherwise specified [NOS], n = 11; and Other, n = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 complete responses [CR],9 partial responses [PR], and 14 stable disease); median time to response was 1.9 months. ORR was 51.9% for AITL/TFH (10 CR, 4 PR) and 31.8% for Other (2 CR, 5 PR); median duration of response was 12.9 and 5.3 months, respectively. The most common grade ≥3 treatment-emergent adverse events were asymptomatic amylase elevation (23.1%), anemia (20.0%), and asymptomatic lipase elevation (18.5%). These data suggest clinical activity and acceptable tolerability for cerdulatinib in patients with relapsed/refractory PTCL.
- Open Access
- 16 January 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (3) , 311-324
Genetic alteration of class I HLA in cutaneous T-cell lymphoma
Abnormalities involving class I HLA are frequent in many lymphoma subtypes but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCLs). We characterized the occurrence of class I HLA abnormalities in 65 patients with advanced mycosis fungoides or Sézary syndrome. Targeted DNA sequencing, including coverage of HLA loci, revealed at least 1 HLA abnormality in 26 of 65 patients (40%). Twelve unique somatic HLA mutations were identified across 9 patients, and loss of heterozygosity or biallelic loss of HLA was found to affect 24 patients. Although specific HLA alleles were commonly disrupted, these events did not associate with a decrease in the total class I HLA expression. Genetic events preferentially disrupted HLA alleles capable of presenting greater numbers of putative neoantigens. HLA abnormalities co-occurred with other genetic immune evasion events and were associated with worse progression-free survival. Single-cell analyses demonstrated that HLA abnormalities were frequently subclonal. Through analysis of serial samples, we observed that disrupting class I HLA events change dynamically over the disease course. The dynamics of HLA disruption are highlighted in a patient who received pembrolizumab and in whom resistance to pembrolizumab was associated with the elimination of an HLA mutation. Overall, our findings show that genomic class I HLA abnormalities are common in advanced CTCL and may be an important consideration in understanding the effects of immunotherapy in CTCL.
- 16 January 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (3) , 311-324
Open AccessGenetic alteration of class I HLA in cutaneous T-cell lymphoma
Abnormalities involving class I HLA are frequent in many lymphoma subtypes but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCLs). We characterized the occurrence of class I HLA abnormalities in 65 patients with advanced mycosis fungoides or Sézary syndrome. Targeted DNA sequencing, including coverage of HLA loci, revealed at least 1 HLA abnormality in 26 of 65 patients (40%). Twelve unique somatic HLA mutations were identified across 9 patients, and loss of heterozygosity or biallelic loss of HLA was found to affect 24 patients. Although specific HLA alleles were commonly disrupted, these events did not associate with a decrease in the total class I HLA expression. Genetic events preferentially disrupted HLA alleles capable of presenting greater numbers of putative neoantigens. HLA abnormalities co-occurred with other genetic immune evasion events and were associated with worse progression-free survival. Single-cell analyses demonstrated that HLA abnormalities were frequently subclonal. Through analysis of serial samples, we observed that disrupting class I HLA events change dynamically over the disease course. The dynamics of HLA disruption are highlighted in a patient who received pembrolizumab and in whom resistance to pembrolizumab was associated with the elimination of an HLA mutation. Overall, our findings show that genomic class I HLA abnormalities are common in advanced CTCL and may be an important consideration in understanding the effects of immunotherapy in CTCL.
- Open Access
- 29 March 2024
- Published by Elsevier in Blood Neoplasia
- Vol. 1 (2)
Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma
- 29 March 2024
- Published by Elsevier in Blood Neoplasia
- Vol. 1 (2)
Open AccessLong-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma